Hikma Pharmaceuticals (LON:HIK) Price Target Cut to GBX 2,400 by Analysts at Deutsche Bank Aktiengesellschaft

Hikma Pharmaceuticals (LON:HIK) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from GBX 2,500 to GBX 2,400 in a research note issued on Friday,Digital Look reports. The firm presently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s target price would suggest a potential upside of 52.91% from the company’s current price.

HIK has been the subject of a number of other reports. JPMorgan Chase & Co. dropped their price target on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a report on Friday, November 7th. Berenberg Bank dropped their price objective on Hikma Pharmaceuticals from GBX 2,510 to GBX 2,300 and set a “buy” rating on the stock in a research note on Thursday, November 6th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,360 price objective on shares of Hikma Pharmaceuticals in a research report on Friday, November 7th. Finally, Peel Hunt reissued a “buy” rating and set a GBX 2,170 price target on shares of Hikma Pharmaceuticals in a research report on Friday, November 7th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Hikma Pharmaceuticals currently has an average rating of “Buy” and an average target price of GBX 2,326.

Hikma Pharmaceuticals Stock Performance

Shares of LON HIK traded up GBX 19.54 during mid-day trading on Friday, hitting GBX 1,569.54. The company had a trading volume of 46,160,910 shares, compared to its average volume of 12,419,596. Hikma Pharmaceuticals has a 12 month low of GBX 1,482 and a 12 month high of GBX 2,360. The firm has a market cap of £3.48 billion, a P/E ratio of 9.40, a PEG ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The business’s 50-day simple moving average is GBX 1,574 and its 200-day simple moving average is GBX 1,743.56.

Insider Activity at Hikma Pharmaceuticals

In other news, insider Victoria Hull acquired 3,214 shares of the stock in a transaction on Friday, November 7th. The stock was acquired at an average cost of GBX 1,547 per share, for a total transaction of £49,720.58. Also, insider Said Darwazah bought 70,000 shares of the stock in a transaction on Friday, November 7th. The shares were acquired at an average cost of GBX 1,541 per share, with a total value of £1,078,700. Insiders have bought 448,214 shares of company stock valued at $712,497,058 over the last three months. 18.15% of the stock is owned by insiders.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.